patient subgroup...
ECOG 0 ECOG 1 Gender, female Gender, male metastasis (brain) NO metastasis (brain) YES PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC1/2 or IC1/2 : ≥1% of TC or IC and <50% of TC and <10% of IC) PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC) PDL1 (TC3 or IC3 : ≥50% of TC or ≥10% of IC ) smoker (current or former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
metastatic/advanced NSCLC (mNSCLC) - 1st line (L1), sintillimab plus SoC , meta-analysis of study results
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
efficacy endpoints 00 deaths (OS) 0.61 [0.40, 0.93]< 1 0% 1 study (1/-) 99.0 % NA not evaluable crucial - progression or deaths (PFS) 0.48 [0.36, 0.64]< 1 0% 1 study (1/-) 100.0 % NA not evaluable important - objective responses (ORR) 2.54 [1.63, 3.97]> 1 0% 1 study (1/-) 100.0 % NA not evaluable non important - safety endpoints 00 AE (any grade) 1.02 [0.03, 30.46]< 1 0% 1 study (1/-) 49.7 % NA not evaluable non important - AE (grade 3-4) 1.13 [0.74, 1.73]< 1 0% 1 study (1/-) 29.1 % NA not evaluable non important - AE leading to death (grade 5) 0.31 [0.11, 0.90]< 1 0% 1 study (1/-) 98.4 % NA not evaluable non important - AE leading to treatment discontinuation (any grade) 0.70 [0.31, 1.55]< 1 0% 1 study (1/-) 81.1 % NA not evaluable non important - AE leading to treatment discontinuation (grade 3-4) 0.64 [0.26, 1.56]< 1 0% 1 study (1/-) 83.6 % NA not evaluable non important - TRAE (grade 3-4) endpoints 00 Diarrhoea TRAE (grade 3-4) 0.49 [0.01, 24.91]< 1 0% 1 study (1/-) 63.6 % NA not evaluable non important - Hyperthyroidism TRAE (grade 3-4) 0.49 [0.01, 24.91]< 1 0% 1 study (1/-) 63.6 % NA not evaluable non important - Hypothyroidism TRAE (grade 3-4) 0.49 [0.01, 24.91]< 1 0% 1 study (1/-) 63.6 % NA not evaluable non important - Increase AST TRAE (grade 3-4) 0.49 [0.01, 24.91]< 1 0% 1 study (1/-) 63.6 % NA not evaluable non important - Increased ALT TRAE (grade 3-4) 0.49 [0.01, 24.91]< 1 0% 1 study (1/-) 63.6 % NA not evaluable non important - Pneumonitis TRAE (grade 3-4) 0.98 [0.09, 10.96]< 1 0% 1 study (1/-) 50.5 % NA not evaluable non important - Pruritus TRAE (grade 3-4) 0.49 [0.01, 24.91]< 1 0% 1 study (1/-) 63.6 % NA not evaluable non important - Rash TRAE (grade 3-4) 0.16 [0.02, 1.56]< 1 0% 1 study (1/-) 94.1 % NA not evaluable non important - AE (grade 3-4) endpoints 00
LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias;
suggested: nominally statistically significant but without a strict control of overall risk of type 1 error;
inconclusive: not nominally statistically significant;
safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies;
published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE.
Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.